AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) ...

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy ...

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today reported financial results for the first quarter of 2025 ...

Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025 Recruitment ongoing in the first in human Phase ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug conjugate (ADC) for breast cancer, Datroway, the latest to emerge from ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast cancer, a few weeks after its ...

Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III IDeate-Esophageal01 study evaluating their B7-H3 directed DXd antibody-drug conjugate (ADC), ifinatamab ...

Investors and consultants in the space said that they have seen rising enthusiasm among investors as recent funding rounds outpace prior hauls.

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer. Bria-IMT plus check point inhibitors had a median ...

As of 8:38:07 CEST. Market open.